A 50-year-old man with non-small cell lung cancer (NSCLC) tests positive for EGFR exon 19 deletion. He is started on osimertinib as first-line therapy. What is the specific pharmacological advantage of osimertinib over first-generation EGFR TKIs (erlotinib, gefitinib) for EGFR-mutant NSCLC?

• A Osimertinib is a third-generation irreversible EGFR inhibitor that selectively inhibits EGFR with activating mutations (exon 19 del, L858R) AND the resistance mutation T790M, while having reduced affinity for wild-type EGFR, resulting in superior CNS penetration and activity against brain metastases ✓
• B Osimertinib has higher affinity for the wild-type EGFR, leading to greater tumor cell killing
• C Osimertinib simultaneously inhibits EGFR and ALK kinases, covering both common driver mutations in NSCLC
• D Osimertinib is an antibody-drug conjugate that irreversibly degrades EGFR protein via PROTAC mechanism

Explanation

First-generation EGFR TKIs (erlotinib, gefitinib) reversibly inhibit mutant and wild-type EGFR with similar affinity. Resistance develops in ~60% through the T790M gatekeeper mutation (methionine replacing threonine 790 restores ATP binding affinity). Osimertinib is a third-generation, mutant-selective, irreversible EGFR TKI that covalently binds Cys797 in the ATP-binding site. Its structural design confers: (1) Selective inhibition of EGFR with activating mutations (L858R, exon 19 del) and T790M resistance mutation; (2) Markedly reduced affinity for wild-type EGFR (reduced skin/GI toxicity); (3) Superior CNS penetration (crosses the blood-brain barrier effectively, reaching therapeutic CSF concentrations), addressing the common problem of CNS progression with first-generation TKIs. FLAURA trial established first-line osimertinib superiority over first-generation TKIs.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.